Imaging sexual response

Abstract

The present invention relates to methods for contrast-enhanced imaging of sexual response. In particular, the present invention relates to methods of magnetic resonance imaging (MRI), computerized X-ray tomography (CT), ultrasound, and optical imaging using contrast agents to measure blood flow during sexual response, especially female sexual response. The invention relates to methods of analyzing normal sexual function and sexual dysfunction and provides a means for evaluating and screening potential therapeutic compounds for enhancing sexual function or treating sexual dysfunction.

1 . A method for measuring the effect of a compound on sexual function comprising the steps of: 
 (a) administering a magnetic resonance imaging contrast agent to a subject;    (b) subjecting the subject to magnetic resonance imaging;    (c) measuring an imaging signal characteristic of the contrast agent to establish a baseline;    (d) subjecting the subject to a stimulus that will assess the sexual function;    (e) monitoring an imaging signal characteristic of the contrast agent to assess the sexual function after stimulus;    (f) administering a compound hypothesized to produce an effect on the sexual function; and    (g) determining if the sexual function has been affected as a result of administration of the compound.    
   
   
       2 . The method according to  claim 1 , wherein the subject has sexual dysfunction.  
   
   
       3 . The method according to  claim 2  wherein the sexual dysfunction is hypoactive sexual desire disorder, sexual aversion disorder, a sexual arousal disorder, an orgasmic disorder, dyspareunia, or vaginismus.  
   
   
       4 . The method according to  claim 3  wherein the sexual arousal disorder is female sexual arousal disorder or male erectile disorder.  
   
   
       5 . The method according to  claim 3  wherein the orgasmic disorder is female orgasmic disorder (formerly, inhibited female orgasm), male orgasmic disorder (formerly, inhibited male orgasm), or premature ejaculation.  
   
   
       6 . The method according to  claim 1 , wherein the magnetic resonance imaging contrast agent is MS-325.  
   
   
       7 . The method according to  claim 1 , wherein the compound hypothesized to produce an effect on the sexual function is Viagra™.  
   
   
       8 . The method according to  claim 1 , wherein the subject has sexual dysfunction and wherein the compound is being tested to determine if it has an effect on the sexual function.  
   
   
       9 . The method according to  claim 8 , wherein the contrast agent is MS-325.  
   
   
       10 . The method according to  claim 8 , wherein the compound hypothesized to produce an effect on the sexual function is Viagra™.  
   
   
       11 . The method according to  claim 1  wherein the subject is a mammal.  
   
   
       12 . The method according to  claim 11  wherein the subject is a human.